Immix Biopharma
IMMX
22 hedge funds and large institutions have $4.9M invested in Immix Biopharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 4 closing their positions.
0.09% more ownership
Funds ownership: 10.44% → 10.53% (+0.09%)
4% less funds holding
Funds holding: 23 → 22 (-1)
22% less capital invested
Capital invested by funds: $6.32M → $4.9M (-$1.41M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$106K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$104K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$24.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$547 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$38.6K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$33K |
| 3 |
CCC
Cable Car Capital
San Francisco,
California
|
-$31.6K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
-$17K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$16.6K |
IMMX Hedge Fund Activity: Q1 2025 in Review
22 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q1 2025, worth a combined $4.9M — down 22% from $6.32M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IMMX and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 4 added.
The largest buyer was Northern Trust, adding an estimated $106K. The largest seller was Jane Street, exiting entirely with an estimated $38.6K sold.
- 22 institutional investors held Immix Biopharma (IMMX) as of Q1 2025, down from 23 in Q4 2024.
- Funds reported $4.9M of Immix Biopharma stock for Q1 2025, down 22% quarter-over-quarter.
- 3 funds opened new Immix Biopharma positions in Q1 2025 and 4 closed out, a net change of -1 holder.
- The largest Immix Biopharma buyer in Q1 2025 was Northern Trust, an estimated $106K added.
- The largest Immix Biopharma seller in Q1 2025 was Jane Street, an estimated $38.6K sold.
Based on aggregated 13F filings for Q1 2025.